Deltaran® (Lyophilisate) Instructions for Use
Marketing Authorization Holder
Comcon Research Center, LLC (Russia)
Manufactured By
State Research Institute of Occupational Health FMBA, FSUE (Russia)
ATC Code
N07BB (Drugs used for alcohol dependence)
Dosage Form
| Deltaran® | Lyophilizate for preparation of solution for intranasal administration 0.3 mg: amp. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Lyophilizate for preparation of solution for intranasal administration in the form of a powder or porous mass of white color.
| 1 amp. | |
| Tryptophanyl-alanyl-glycyl-glycyl-aspartyl-alanyl-seryl-glycyl-glutamic acid (delta sleep-inducing peptide) | 0.3 mg |
Excipients: glycine – 0.3 mg.
0.3 mg – ampoules (5) – contour cell packaging (1) – cardboard packs.
0.3 mg – ampoules (10) – contour cell packaging (1) – cardboard packs.
Clinical-Pharmacological Group
Drug for the treatment of alcohol dependence
Pharmacotherapeutic Group
Antihypoxant
Pharmacological Action
Synthetic nonapeptide, similar in structure to an endogenous substance of the human body. This peptide is present both in the human body and in the bodies of mammalian animals and does not exhibit any toxic properties.
The synthesized peptide is completely identical to the natural peptide produced in the body, known as delta sleep-inducing peptide, which possesses a wide spectrum of pharmacological action: neuroprotective, anti-stress, antioxidant, anticonvulsant, antihypoxic, antitoxic, and geroprotective. When entering the body, the exogenous delta sleep-inducing peptide compensates for the deficiency of the endogenous peptide, whether absolute or functional, which allows controlling neurons to work as adequately as possible under conditions of any type of stress and to counteract the occurrence of metabolic deviations from physiological norms.
It reduces pathological craving for alcohol and relieves manifestations of alcohol withdrawal. The mechanism of action is not known.
Pharmacokinetics
Delta sleep-inducing peptide is rapidly degraded in the body into individual amino acids and short peptides by proteolytic enzymes of the blood and is eliminated from the body.
Indications
As part of complex therapy: treatment and prevention of stress-induced conditions; alcohol withdrawal syndrome and primary pathological craving for alcohol.
ICD codes
| ICD-10 code | Indication |
| F10.2 | Chronic alcoholism |
| F10.3 | Withdrawal state |
| F43 | Reaction to severe stress and adjustment disorders |
| ICD-11 code | Indication |
| 6B4Z | Disorders specifically associated with stress, unspecified |
| 6C40.2Z | Alcohol dependence, unspecified |
| 6C40.4Z | Alcohol withdrawal syndrome, unspecified |
| 6C40.Z | Disorders due to alcohol use, unspecified |
| 8D44.Y | Other specified alcohol-related neurological disorders |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer intranasally only after reconstitution.
Reconstitute the lyophilisate in one ampoule with 1-2 mL of water for injection or 0.9% sodium chloride solution immediately before use.
For alcohol withdrawal syndrome, use a dose of 0.3 mg ( one reconstituted ampoule) three times a day for 5-7 days.
For pathological craving for alcohol, use a dose of 0.3 mg ( one reconstituted ampoule) twice a day for 10-14 days.
For stress-induced conditions, use a dose of 0.3 mg ( one reconstituted ampoule) once or twice a day for 5-10 days.
Adjust the treatment duration individually based on clinical response and severity of the condition.
Avoid use in the presence of acute rhinitis or nasal inflammation; if necessary, administer only after washing the nose or relieving congestion.
Do not exceed the recommended daily dose.
Adverse Reactions
Possible allergic reactions, irritation of the nasal mucosa.
Contraindications
Hypersensitivity to the active substance; pregnancy, breastfeeding period; age under 18 years.
Use in Pregnancy and Lactation
Contraindicated during pregnancy and breastfeeding.
Pediatric Use
Contraindicated for use in children and adolescents under 18 years of age.
Special Precautions
In inflammatory diseases of the nose (acute rhinitis), the absorption efficiency of the delta sleep-inducing peptide by the mucous membrane may be reduced. In such cases, it is recommended to administer the agent after washing the nose or eliminating congestion with medications.
It is not recommended to use the agent in cases of severe bradycardia.
In severe conditions (alcohol withdrawal), it is necessary to consult a doctor for the prescription of additional detoxification medications.
Storage Conditions
Store at 2°C (36°F) to 15°C (59°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer